NO20051669L - Fremgangsmater og reagenser for behandling av sykdommer og forstyrrelser assosiert med okte nivaer av proinflammatoriske cytokiner - Google Patents

Fremgangsmater og reagenser for behandling av sykdommer og forstyrrelser assosiert med okte nivaer av proinflammatoriske cytokiner

Info

Publication number
NO20051669L
NO20051669L NO20051669A NO20051669A NO20051669L NO 20051669 L NO20051669 L NO 20051669L NO 20051669 A NO20051669 A NO 20051669A NO 20051669 A NO20051669 A NO 20051669A NO 20051669 L NO20051669 L NO 20051669L
Authority
NO
Norway
Prior art keywords
treatment
reagents
diseases
methods
disorders associated
Prior art date
Application number
NO20051669A
Other languages
English (en)
Norwegian (no)
Inventor
Curtis Keith
Jason Fong
Palaniyandi Manivasakam
James M Nichols
Grant R Zimmermann
Daniel Grau
Brendan Smith
Benjamin A Auspitz
Bradley B Brasher
Noah Sachs
Todd W Chappell
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32074779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20051669(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of NO20051669L publication Critical patent/NO20051669L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20051669A 2002-09-24 2005-04-04 Fremgangsmater og reagenser for behandling av sykdommer og forstyrrelser assosiert med okte nivaer av proinflammatoriske cytokiner NO20051669L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US41304002P 2002-09-24 2002-09-24
US41726102P 2002-10-09 2002-10-09
US42752602P 2002-11-19 2002-11-19
US42742402P 2002-11-19 2002-11-19
US46475303P 2003-04-23 2003-04-23
PCT/US2003/030156 WO2004030618A2 (fr) 2002-09-24 2003-09-24 Methodes et reactifs destines au traitement de maladies et de troubles associes a des niveaux accrus de cytokines pro-inflammatoires

Publications (1)

Publication Number Publication Date
NO20051669L true NO20051669L (no) 2005-06-10

Family

ID=32074779

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051669A NO20051669L (no) 2002-09-24 2005-04-04 Fremgangsmater og reagenser for behandling av sykdommer og forstyrrelser assosiert med okte nivaer av proinflammatoriske cytokiner

Country Status (12)

Country Link
EP (1) EP1553955A4 (fr)
JP (1) JP2006503905A (fr)
AR (1) AR041386A1 (fr)
AU (1) AU2003299196A1 (fr)
BR (1) BR0314713A (fr)
CA (1) CA2509526A1 (fr)
HR (1) HRP20050355A2 (fr)
IS (1) IS7811A (fr)
MX (1) MXPA05003152A (fr)
NO (1) NO20051669L (fr)
TW (1) TW200422042A (fr)
WO (1) WO2004030618A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004212919A1 (en) * 2003-02-14 2004-09-02 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders
CA2538023A1 (fr) * 2003-09-24 2005-04-07 Combinatorx, Incorporated Schemas posologiques therapeutiques pour une administration de combinaisons de medicaments
MXPA06013463A (es) * 2004-05-17 2007-03-01 Combinatorx Inc Metodos y reactivos para el tratamiento de desordenes inmuno-inflamatorios.
AU2011236053B2 (en) * 2004-11-19 2014-06-26 Merck Sharpe & Dohme B.V. Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
CA2585317C (fr) * 2004-11-19 2015-02-24 N.V. Organon Association de medicaments pour le traitement de depressions et de troubles s'y rapportant, comprenant un inhibiteur selectif de la recapture dela serotonine depression
EP1719507B1 (fr) * 2005-04-13 2010-07-14 Astion Development A/S Des agonistes de bêta-2 adrénocepteur pour le traitement de maladies des tissus conjonctifs de la peau
JP4832806B2 (ja) * 2005-06-03 2011-12-07 久光製薬株式会社 経皮投与製剤
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
EP2059234B1 (fr) * 2006-09-08 2011-11-02 Ore Pharmaceuticals Inc. Procédé pour réduire ou soulager une inflammation dans le tube digestif
WO2008033754A2 (fr) * 2006-09-11 2008-03-20 Duke University Méthodes et compositions de traitement de la dépression vasculaire.
GB0701171D0 (en) * 2007-01-22 2007-02-28 Imp Innovations Ltd Compositions and uses thereof
WO2010098230A1 (fr) * 2009-02-27 2010-09-02 久光製薬株式会社 Préparation transdermique
PT117765A (pt) * 2022-01-28 2023-07-28 Faculdade De Farmacia Da Univ De Lisboa Formulação tópica de fluvoxamina para o tratamento de psoríase
WO2024074699A1 (fr) * 2022-10-07 2024-04-11 Oculis Operations Sarl Microsuspensions de gouttes oculaires d'inhibiteurs de mtor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007863A1 (fr) * 1991-10-15 1993-04-29 Mullarkey Michael F Procedes et compositions servant a traiter des reactions allergiques
GB9603137D0 (en) * 1996-02-15 1996-04-17 Merck Sharp & Dohme Therapeutic agents
ES2259746T3 (es) * 1996-07-15 2006-10-16 Alza Corporation Nuevas formulaciones para la administracion transdermica de fluoxetina.
CA2282845A1 (fr) * 1997-03-18 1998-09-24 Basf Aktiengesellschaft Procedes et compositions permettant de moduler la sensibilite aux corticosteroides
US6281248B1 (en) * 2000-02-16 2001-08-28 Magda Abdel Fattah Ahmed Composition for treating asthma
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs

Also Published As

Publication number Publication date
HRP20050355A2 (en) 2005-10-31
WO2004030618A2 (fr) 2004-04-15
JP2006503905A (ja) 2006-02-02
MXPA05003152A (es) 2006-04-27
WO2004030618A3 (fr) 2005-04-07
BR0314713A (pt) 2005-07-26
EP1553955A4 (fr) 2008-11-05
AR041386A1 (es) 2005-05-18
IS7811A (is) 2005-04-19
CA2509526A1 (fr) 2004-04-15
EP1553955A2 (fr) 2005-07-20
AU2003299196A1 (en) 2004-04-23
TW200422042A (en) 2004-11-01

Similar Documents

Publication Publication Date Title
NO20051669L (no) Fremgangsmater og reagenser for behandling av sykdommer og forstyrrelser assosiert med okte nivaer av proinflammatoriske cytokiner
NO20053678L (no) Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser
WO2005079284A3 (fr) Methodes et reactifs pour le traitement de maladies et de troubles lies a des niveaux accrus de cytokines proinflammatoires
NO20062363L (no) Fremgangsmater og reagenser for behandling av inflammatoriske forstyrrelser
Erdes et al. Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults
NO20061239L (no) Fremgangsmater og reagenser for behandling av immunoinflammatoriske forstyrrelser
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
Florensa-Zanuy et al. Cannabidiol antidepressant-like effect in the lipopolysaccharide model in mice: Modulation of inflammatory pathways
NO20035473D0 (no) Oralt administrerte doseringsformer av GABA-analogprodrugs som har reduserttoksisitet
Intiso The rehabilitation role in chronic kidney and end stage renal disease
NO20062300L (no) Fremgangsmater og reagenser for behandling av inflammatoriske forstyrelser
Ali et al. Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome
JP2017528483A5 (fr)
NO20052272L (no) CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom
NO20064964L (no) Behandling av svekket respiratorisk funksjon
Allen-Philbey et al. Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis
WO2006138372A3 (fr) Procedes et reactifs pour le traitement de troubles inflammatoires
Zhu et al. Early effects of mechanical ventilation on isotonic contractile properties and MAF-box gene expression in the diaphragm
WO2007139753A3 (fr) Méthodes et compositions pour le traitement de maladies ou d'affections associées à des taux accrus de protéine c réactive, d'interleukine 6 ou d'interféron gamma
He et al. Long COVID: The latest manifestations, mechanisms, and potential therapeutic interventions
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
Gast et al. CD40 activation induces NREM sleep and modulates genes associated with sleep homeostasis
WO2006063256A3 (fr) Traitement au moyen de d-threo methylphenidate

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application